Phaxiam Therapeutics

Phaxiam Therapeutics company information, Employees & Contact Information

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Company Details

Employees
72
Founded
-
Address
60 Avenue Rockefeller, Bâtiment Bioserra,france
Industry
Biotechnology
HQ
LYON, Rhône-Alpes
Looking for a particular Phaxiam Therapeutics employee's phone or email?

Phaxiam Therapeutics Questions

News

Erytech's shares plunge on failure of eryaspase in pancreatic cancer trial - FirstWord Pharma

Erytech's shares plunge on failure of eryaspase in pancreatic cancer trial FirstWord Pharma

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 - Yahoo Finance

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 Yahoo Finance

Erytech's merger with Pherecydes reaches the finish line after contentious few months - Fierce Biotech

Erytech's merger with Pherecydes reaches the finish line after contentious few months Fierce Biotech

Catalent pays Erytech $44.5m for NJ cell therapy plant - BioProcess International

Catalent pays Erytech $44.5m for NJ cell therapy plant BioProcess International

ERYTECH Pharma (ERYP) Stock Price, News & Analysis - MarketBeat

ERYTECH Pharma (ERYP) Stock Price, News & Analysis MarketBeat

ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70% - Equity.Guru

ERYTECH Pharma (ERYP.Q) has a GRASPA® on ALL, shares up +70% Equity.Guru

Erytech begins Phase II trial of eryaspase to treat ALL - Clinical Trials Arena

Erytech begins Phase II trial of eryaspase to treat ALL Clinical Trials Arena

Erytech Abandons BLA Plans for Leukemia Drug, Citing Competitive Market - BioSpace

Erytech Abandons BLA Plans for Leukemia Drug, Citing Competitive Market BioSpace

Catalent snaps up New Jersey cell therapy plant for $44.5M days after revealing big biologics expansion - Fierce Pharma

Catalent snaps up New Jersey cell therapy plant for $44.5M days after revealing big biologics expansion Fierce Pharma

SQZ, Erytech kick off $57M cell therapy partnership; Jean-Paul Kress lands new CEO gig at MorphoSys - Endpoints News

SQZ, Erytech kick off $57M cell therapy partnership; Jean-Paul Kress lands new CEO gig at MorphoSys Endpoints News

Erytech Pharma taps new scientific, business chiefs | Personnel Moves, Oct. 26, 2016 - Drug Delivery Business

Erytech Pharma taps new scientific, business chiefs | Personnel Moves, Oct. 26, 2016 Drug Delivery Business

Engineering Red Blood Cells to Fight the Most Severe Cancers - Labiotech.eu

Engineering Red Blood Cells to Fight the Most Severe Cancers Labiotech.eu

Gil Beyen, CEO and Chairman of ERYTECH Pharma, Explains the Phase III Cancer Cure from his Company - The Wall Street Transcript

Gil Beyen, CEO and Chairman of ERYTECH Pharma, Explains the Phase III Cancer Cure from his Company The Wall Street Transcript

By merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy - Fierce Biotech

By merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy Fierce Biotech

Erytech shifts focus to leukemia as lead drug flunks late-stage pancreatic cancer trial - Fierce Biotech

Erytech shifts focus to leukemia as lead drug flunks late-stage pancreatic cancer trial Fierce Biotech

EuroBiotech Report—Novartis CAR-T, Shire-Roche, Zealand IPO, Erytech alliance and Enterome-Nestlé joint venture - Fierce Biotech

EuroBiotech Report—Novartis CAR-T, Shire-Roche, Zealand IPO, Erytech alliance and Enterome-Nestlé joint venture Fierce Biotech

Top Phaxiam Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant